Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study - Gynecologic Oncology
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study | Future Oncology
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count : results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib in the PRIMA Trial
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
First-line niraparib is associated with improvement in QA-PFS and QA-TWiST
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
The latest clinical evidence on PARP inhibitor maintenance therapy - ppt download
Current Oncology | Free Full-Text | A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
PARP Inhibitors. - ppt download
